(News Bulletin 247) – Invest Securities maintains its advice to buy Icade shares, with a price target reduced from 60 to 57.2 euros.
‘No solution in terms of liquidity for Icade Santé has been approved to date but it would probably include the sale of all or part of Icade’s stake in Icade Santé’, indicates the analysis office.
‘Despite the attraction of an increased distribution and a share buyback limiting dilution in a scenario of total sale of Icade Santé (2.6 billion euros), a scenario of sale of 58% of the stake ( €1.5bn) would allow Icade to retain a substantial share of healthcare assets (16%) to compensate for the difficulties of the tertiary asset portfolio and the volatility of property development”, estimates the broker.
Invest Securities thinks that a partial or full divestiture could be positive in the short term, but more questionable in the long term.
Anyway, ‘the two scenarios show a potential for a stock market revaluation of the title in one year’, underlines Invest.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
